{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:34:48Z","timestamp":1794062088858,"version":"4.8.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Sorafenib included in Chinese medical insurance is the earliest targeted drug for radioactive iodine refractory differentiated thyroid cancer (RR-DTC). This study is to further demonstrate the clinical efficacy and safety of sorafenib used in Zhujiang Hospital of Southern Medical University.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>RR-DTC patients treated at our Department of Nuclear Medicine in Zhujiang Hospital of Southern Medical University (October 2017\u2013May 2020) were retrospectively analyzed. Treatment effects, progression-free survival (PFS), and adverse effects (AEs) during medication were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 31 patients included, 26 patients were evaluated for efficacy with a median follow-up time of 17.5 months (4.0\u201351.0 months). The disease control rate (DCR) was 57.7% (<jats:italic>n<\/jats:italic> = 15) and the objective response rate (ORR) was 26.9% (<jats:italic>n<\/jats:italic>\u00a0= 7). Most patients with disease control had thyroglobulin decreases of more than 60% (<jats:italic>p<\/jats:italic> = 0.004), ORRs were favorable in patients with lung metastasis and lung-only metastasis (<jats:italic>p<\/jats:italic> = 0.010 and 0.001, respectively). The PFS of the 26 patients analyzed was 16.5 months (95%CI: 14.41 \u201323.90 months). In the subgroup analysis, female, patients with lung-only metastasis, hand-foot skin syndrome (HFS), and thyroglobulin response \u2265 60% observed longer PFS (<jats:italic>p<\/jats:italic> = 0.038, 0.045, 0.035, and 0.000, respectively), while patients with bone metastasis had lower PFS (<jats:italic>p<\/jats:italic> = 0.035). The most common toxicity profile was HFS (93.5%), followed by diarrhea (83.9%), alopecia (74.2%). All the side effects were mainly grade 1\u20132. Grade 3\u20134 adverse reactions were more common in diarrhea and HFS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Sorafenib has promising efficacy in RR-DTC, especially in patients with lung metastasis and lung-only metastasis. The AEs of sorafenib were generally mild, and the main AE was HFS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1200932","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T11:53:55Z","timestamp":1689681235000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib"],"prefix":"10.3389","volume":"14","author":[{"given":"Yuanna","family":"Ling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanliang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30172-6","article-title":"Thyroid cancer","volume":"388","author":"Cabanillas","year":"2016","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.17352\/ijcem.000040","article-title":"Therapeutic options for advanced thyroid cancer","volume":"5","author":"Jayarangaiah","year":"2019","journal-title":"Int J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2019.34.3.215","article-title":"Radioactive iodine-refractory differentiated thyroid cancer and redifferentiation therapy","volume":"34","author":"Liu","year":"2019","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocr Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0654","article-title":"Long-term prognosis of differentiated thyroid cancer with lung metastasis in Korea and its prognostic factors","volume":"24","author":"Cho","year":"2014","journal-title":"Thyroid"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-006-0393-4","article-title":"Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models","volume":"59","author":"Chang","year":"2007","journal-title":"Cancer Chemoth Pharm"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0356","article-title":"Tertiary care experience of sorafenib in the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma: a Korean multicenter study","volume":"28","author":"Kim","year":"2018","journal-title":"Thyroid"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00384","article-title":"Safety of tyrosine kinase inhibitors in patients with differentiated thyroid cancer: real-world use of lenvatinib and sorafenib in Korea","volume":"10","author":"Kim","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0633","article-title":"Clinicopathological features predict outcomes in patients with radioiodine-refractory differentiated thyroid cancer treated with sorafenib: a real-world study","volume":"25","author":"Cheng","year":"2020","journal-title":"Oncologist"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2020.04.021","article-title":"Experience of sorafenib treatment in differentiated thyroid cancer from Taiwan","volume":"120","author":"Lin","year":"2021","journal-title":"J Formos Med Assoc"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0825","article-title":"Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network","volume":"170","author":"Massicotte","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/OTT.S70670","article-title":"Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population","volume":"8","author":"Benekli","year":"2015","journal-title":"Onco Targets Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0702","article-title":"Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma","volume":"161","author":"Hoftijzer","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65515-0","article-title":"Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features","volume":"155","author":"Bunone","year":"1999","journal-title":"Am J Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.2.7226","article-title":"Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma","volume":"86","author":"Klein","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bone.2010.05.007","article-title":"The bone remodeling environment is a factor in breast cancer bone metastasis","volume":"48","author":"Ooi","year":"2011","journal-title":"Bone"},{"key":"B26","article-title":"Cellular and hormonal mechanisms associated with malignant bone resorption","volume":"71","author":"Quinn","year":"1994","journal-title":"Lab Invest"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3390\/ijms18071345","article-title":"Development of bone targeting drugs","volume":"18","author":"Stapleton","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2021.11.004","article-title":"Sex differences in papillary thyroid cancer","volume":"271","author":"Remer","year":"2022","journal-title":"J Surg Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/0959-8049(93)90574-y","article-title":"Prognostic importance of various clinicopathological features in papillary thyroid carcinoma","author":"Akslen","year":"1992","journal-title":"Eur J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0492","article-title":"A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later","volume":"90","author":"Kloos","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.0355","article-title":"Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy","volume":"21","author":"Miyauchi","year":"2011","journal-title":"Thyroid"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-21-0024","article-title":"Redifferentiation-facilitated radioiodine therapy in thyroid cancer","volume":"28","author":"Lamartina","year":"2021","journal-title":"Endocr-Relat Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70215-8","article-title":"Definition and management of radioactive iodine-refractory differentiated thyroid cancer","volume":"2","author":"Schlumberger","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70203-5","article-title":"Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study","volume":"11","author":"Bible","year":"2010","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9566","article-title":"Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.04.021","article-title":"Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: a meta-analysis of 57 randomized controlled trials involving 24,956 patients","volume":"83","author":"Ding","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1141","article-title":"Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy","volume":"15","author":"Azad","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1159\/000481241","article-title":"Hand-foot syndrome and post-progression treatment are the good predictors of better survival in advanced hepatocellular carcinoma treated with sorafenib: a multicenter study","volume":"93","author":"Ogawa","year":"2017","journal-title":"Oncology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/1756-9966-29-95","article-title":"Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib","volume":"29","author":"Jain","year":"2010","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1200932\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T11:53:58Z","timestamp":1689681238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1200932\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":39,"alternative-id":["10.3389\/fendo.2023.1200932"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1200932","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"article-number":"1200932"}}